Symposiums

Details of a hypothetical 24-year-old female with a longstanding history of recurrent abdominal pain were presented. Over the previous 10 years, she had presented at the ED once or twice yearly with episodes of severe abdominal pain. At her last ED visit, her abdominal pain was debilitating and overwhelming (9–10/10 in severity). Liver function tests were mildly elevated, but blood counts, inflammatory markers, renal function tests, and urine analysis were all normal. Abdominal imaging (ultrasound and CT) and gynaecological examination were also normal. She was discharged from the ED without a specific diagnosis, but was referred for oesophagogastroduodenoscopy and colonoscopy, which were normal.

Although approximately 60% of patients with diffuse large B-cell lymphoma (DLBCL) can be cured, the remaining 40% have relapsed or refractory disease (R/R DLBCL). Substantial unmet need remains for effective, safe therapies for these patients. Novel targeted approaches to the treatment of R/R DLBCL include CD19-directed antibodies, antibody–drug conjugates, bispecific monoclonal antibodies, and anti-CD-19 chimeric antigen receptor (CAR) T-cell therapies.

The latest international guidelines on urticaria were published in September as a joint initiative from the European Academy of…

Recent years have witnessed significant advances in the understanding of facial anatomy. Extensive studies have uncovered the arrangement of soft-tissue layers underlying the skin and their mobility during expression. Meanwhile, increasing awareness of the facial vascular network has laid the foundation for lower risk cosmetic procedures.

‘The Ominous Quartet’ represents four glycaemic disorders at the centre of cardiovascular diseases in diabetes, including ambient…

The symposium featured three talks and a live Q&A session. First, the current patient journey and standards of care in oesophageal cancer…

The chronic inflammatory diseases axial spondyloarthritis (AxS) and psoriatic arthritis (PsA) involve symptoms such as axial skeleton pain…

Richard B. Warren highlighted Psoriasis Symptoms and Impacts Measure (P-SIM) responses from the Phase III BE VIVID trial in patients…